Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD

Authors Barbara P Yawn, Ibrahim Raphiou, Judith S Hurley, et al

Published 1 June 2010 Volume 2010:5 Pages 165—178

DOI https://doi.org/10.2147/COPD.S4159

Review by Single-blind

Peer reviewer comments 2

Barbara P Yawn1, Ibrahim Raphiou2, Judith S Hurley3, Anand A Dalal2

1Olmsted Medical Center, University of Minnesota, Rochester, Minnesota, USA; 2GlaxoSmithKline, Research Triangle Park, North Carolina, USA; 3Hurley Consulting, Placitas, New Mexico, USA

Abstract: Exacerbations contribute significantly to the morbidity of COPD, leading to an accelerated decline in lung function, reduced functional status, reduced health status and quality of life, poorer prognosis and increased mortality. Prevention of exacerbations is thus an important goal of COPD management. In patients with COPD, treatment with a combination of the inhaled corticosteroid fluticasone propionate (250 μg) and the long-acting β2-agonist salmeterol (50 μg) in a single inhaler (250/50 μg) is an effective therapy option that has been shown to reduce the frequency of exacerbations, to improve lung function, dyspnea and health status, and to be relatively cost-effective as a COPD maintenance therapy. Importantly, results of various studies suggest that fluticasone propionate and salmeterol have synergistic effects when administered together that improve their efficacy in controlling symptoms and reducing exacerbations. The present non-systematic review summarizes the role of fluticasone propionate/salmeterol combination therapy in the prevention of exacerbations of COPD and its related effects on lung function, survival, health status, and healthcare costs.

Keywords: Advair, COPD, disease exacerbation, fluticasone propionate, salmeterol, combination drug therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States

Diette GB, Dalal AA, D’Souza AO, Lunacsek OE, Nagar SP

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:415-422

Published Date: 24 February 2015

Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims

Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:573-581

Published Date: 9 November 2011

Direct costs of chronic obstructive pulmonary disease among managed care patients

Anand A Dalal, Laura Christensen, Fang Liu, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:341-349

Published Date: 30 September 2010

Readers of this article also read:

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation

Zaharie F, Cojocneanu-Petric R, Muresan M, Frinc I, Dima D, Petrushev B, Tanase A, Berce C, Chitic M, Berindan-Neagoe I, Pileczki V, Irimie A, Tomuleasa C

International Journal of Nanomedicine 2015, 10:4897-4899

Published Date: 31 July 2015

Efficacy and feasibility of the immunomagnetic separation based diagnosis for detecting sentinel lymph node metastasis from breast cancer

Zhi XC, Zhang M, Meng TT, Zhang XB, Shi ZD, Liu Y, Liu JJ, Zhang S, Zhang J

International Journal of Nanomedicine 2015, 10:2775-2784

Published Date: 7 April 2015

Significant improvement of biocompatibility of polypropylene mesh for incisional hernia repair by using poly-ε-caprolactone nanofibers functionalized with thrombocyte-rich solution

Plencner M, Prosecká E, Rampichová M, East B, Buzgo M, Vysloužilová L, Hoch J, Amler E

International Journal of Nanomedicine 2015, 10:2635-2646

Published Date: 1 April 2015

Inhibition of oxygen scavengers realized by peritoneal macrophages: an adhesion prevention target?

Mynbaev OA, Eliseeva MY, Kadayifci OT, Benhidjeb T, Stark M

International Journal of Nanomedicine 2014, 9:5259-5260

Published Date: 14 November 2014

Synthesis, characterization, and antimicrobial activity of an ampicillin-conjugated magnetic nanoantibiotic for medical applications

Hussein-Al-Ali SH, El Zowalaty ME, Hussein MZ, Geilich BM, Webster TJ

International Journal of Nanomedicine 2014, 9:3801-3814

Published Date: 8 August 2014

Safety of indacaterol in the treatment of patients with COPD

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:477-492

Published Date: 22 September 2011

Fatigue in patients with COPD participating in a pulmonary rehabilitation program

Cindy J Wong, Donna Goodridge, Darcy D Marciniuk, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:319-326

Published Date: 13 September 2010

Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies

Eric Bateman, Dave Singh, David Smith, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:197-208

Published Date: 9 June 2010